Article Details
Retrieved on: 2021-10-21 00:11:07
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn.
Article found on: pharmaceutical-business-review.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here